Abstract B098: An integrated fragment approach yields ABBV-973, a potent, pan-allele small molecule STING agonist for intravenous administration
Kenneth D. Bromberg(AbbVie (United States)), Andrew S. Judd(AbbVie (United States)), Zhiqin Ji(AbbVie (United States)), Albert Lai(AbbVie (United States)), Sven Malchow(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Tanushree Samanta(AbbVie (United States)), Jennifer Gruber(AbbVie (United States)), Heath A. Smith(AbbVie (United States)), Chaohong Sun(AbbVie (United States)), Min Cheng(AbbVie (United States)), Douglas E. Kline(AbbVie (United States))
Cited by 0
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer
|Journal of Medicinal Chemistry|2004|364
Predicting the efficacy of radiotherapy in individual glioblastoma patients<i>in vivo:</i>a mathematical modeling approach
|Physics in Medicine and Biology|2010|294